

# Stephen P Schoenberger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11706470/publications.pdf>

Version: 2024-02-01

76  
papers

11,463  
citations

94381

37  
h-index

66879

78  
g-index

81  
all docs

81  
docs citations

81  
times ranked

12298  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined assessment of MHC binding and antigen abundance improves T cell epitope predictions. <i>IScience</i> , 2022, 25, 103850.	1.9	13
2	Developmentally distinct CD4 <sup>+</sup> T <sub>reg</sub> lineages shape the CD8 <sup>+</sup> T cell response to acute <i>Listeria</i> infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2113329119.	3.3	4
3	Single-cell analysis of immune repertoires enabled. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, e2100106118.	3.3	0
4	The Cancer Epitope Database and Analysis Resource: A Blueprint for the Establishment of a New Bioinformatics Resource for Use by the Cancer Immunology Community. <i>Frontiers in Immunology</i> , 2021, 12, 735609.	2.2	10
5	TLR9 Sensing of Self-DNA Controls Cell-Mediated Immunity to <i>Listeria</i> Infection via Rapid Conversion of Conventional CD4 <sup>+</sup> T Cells to Treg. <i>Cell Reports</i> , 2020, 31, 107249.	2.9	9
6	Harnessing neoantigen specific CD4 T cells for cancer immunotherapy. <i>Journal of Leukocyte Biology</i> , 2020, 107, 625-633.	1.5	40
7	A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 491.	2.2	23
8	Leveraging TCR Affinity in Adoptive Immunotherapy against Shared Tumor/Self-Antigens. <i>Cancer Immunology Research</i> , 2019, 7, 40-49.	1.6	17
9	Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome?. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a028837.	2.3	7
10	Class-B CpG-ODN Formulated With a Nanostructure Induces Type I Interferons-Dependent and CD4 <sup>+</sup> T Cell-Independent CD8 <sup>+</sup> T-Cell Response Against Unconjugated Protein Antigen. <i>Frontiers in Immunology</i> , 2018, 9, 2319.	2.2	13
11	Notch signaling maintains T cell memories. <i>Nature Medicine</i> , 2015, 21, 16-18.	15.2	7
12	FoxO3 is a negative regulator of primary CD8 <sup>+</sup> T cell expansion but not of memory formation. <i>Immunology and Cell Biology</i> , 2015, 93, 120-125.	1.0	16
13	Mutant MHC class II epitopes drive therapeutic immune responses to cancer. <i>Nature</i> , 2015, 520, 692-696.	13.7	1,030
14	CD28 Promotes Plasma Cell Survival, Sustained Antibody Responses, and BLIMP-1 Upregulation through Its Distal PYAP Proline Motif. <i>Journal of Immunology</i> , 2015, 194, 4717-4728.	0.4	56
15	Invariant NKT Cells Induce Plasmacytoid Dendritic Cell (DC) Cross-Talk with Conventional DCs for Efficient Memory CD8 <sup>+</sup> T Cell Induction. <i>Journal of Immunology</i> , 2013, 190, 5609-5619.	0.4	43
16	SLAT Regulates CD8 <sup>+</sup> T Cell Clonal Expansion in a Cdc42- and NFAT1-Dependent Manner. <i>Journal of Immunology</i> , 2013, 190, 174-183.	0.4	15
17	CD69 guides CD4 <sup>+</sup> T cells to the seat of memory. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 8358-8359.	3.3	20
18	Nab2 regulates secondary CD8 <sup>+</sup> T-cell responses through control of TRAIL expression. <i>Blood</i> , 2012, 119, 798-804.	0.6	21

#	ARTICLE	IF	CITATIONS
19	The CD4+ T-cell help signal is transmitted from APC to CD8+ T-cells via CD27â€“CD70 interactions. <i>Nature Communications</i> , 2012, 3, 948.	5.8	97
20	Polyfunctional CD4+ T Cell Responses to Immunodominant Epitopes Correlate with Disease Activity of Virulent Salmonella. <i>PLoS ONE</i> , 2012, 7, e43481.	1.1	21
21	Autocrine IL-2 is required for secondary population expansion of CD8+ memory T cells. <i>Nature Immunology</i> , 2011, 12, 908-913.	7.0	214
22	Interleukin-2 rescues helpless effector CD8+ T cells by diminishing the susceptibility to TRAIL mediated death. <i>Immunology Letters</i> , 2011, 139, 25-32.	1.1	16
23	Differential B7â€“CD28 Costimulatory Requirements for Stable and Inflationary Mouse Cytomegalovirus-Specific Memory CD8 T Cell Populations. <i>Journal of Immunology</i> , 2011, 186, 3874-3881.	0.4	52
24	B7-Mediated Costimulation of CD4 T Cells Constrains Cytomegalovirus Persistence. <i>Journal of Virology</i> , 2011, 85, 390-396.	1.5	28
25	Immune Adjuvant Efficacy of CpG Oligonucleotide in Cancer Treatment Is Founded Specifically upon TLR9 Function in Plasmacytoid Dendritic Cells. <i>Cancer Research</i> , 2011, 71, 6428-6437.	0.4	99
26	Sustained antibody responses depend on CD28 function in bone marrowâ€“resident plasma cells. <i>Journal of Experimental Medicine</i> , 2011, 208, 1435-1446.	4.2	156
27	Mucosal memory CD8+ T cells are selected in the periphery by an MHC class I molecule. <i>Nature Immunology</i> , 2011, 12, 1086-1095.	7.0	63
28	The TNFR family members OX40 and CD27 link viral virulence to protective T cell vaccines in mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 296-307.	3.9	65
29	Sustained Antibody Responses Depend on CD28 Function in Bone Marrow Resident Plasma Cells. <i>Blood</i> , 2011, 118, 182-182.	0.6	6
30	Enhancement of proliferation and downregulation of TRAIL expression on CD8<sup>+</sup> T cells by ILâ€“21. <i>European Journal of Immunology</i> , 2010, 40, 2990-2992.	1.6	6
31	Distinct roles of cytolytic effector molecules for antigenâ€“restricted killing by CTL in vivo. <i>Immunology and Cell Biology</i> , 2010, 88, 761-765.	1.0	13
32	Effectors and memories: Bcl-6 and Blimp-1 in T and B lymphocyte differentiation. <i>Nature Immunology</i> , 2010, 11, 114-120.	7.0	450
33	Plasticity in programming of effector and memory CD8<sup>+</sup> Tâ€“cell formation. <i>Immunological Reviews</i> , 2010, 235, 190-205.	2.8	176
34	TRAIL-expressing CD8+ T cells mediate tolerance following soluble peptide-induced peripheral T cell deletion. <i>Journal of Leukocyte Biology</i> , 2010, 88, 1217-1225.	1.5	18
35	Separate Roles for Antigen Recognition and Lymph Node Inflammation in CD8+ Memory T Cell Formation. <i>Journal of Immunology</i> , 2010, 185, 3167-3173.	0.4	5
36	Preferential Use of B7.2 and Not B7.1 in Priming of Vaccinia Virus-Specific CD8 T Cells. <i>Journal of Immunology</i> , 2009, 182, 2909-2918.	0.4	32

#	ARTICLE	IF	CITATIONS
37	Ex Uno Plura. <i>Science</i> , 2009, 323, 466-467.	6.0	5
38	The TRAIL of Helpless CD8+T Cells in HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 1175-1183.	0.5	15
39	Cutting Edge: Murine Cytomegalovirus Induces a Polyfunctional CD4 T Cell Response. <i>Journal of Immunology</i> , 2008, 180, 6472-6476.	0.4	95
40	Adoptive Therapy with T Cells/NK Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 33-42.	2.0	15
41	Efficient T Cell Activation via a Toll-Interleukin 1 Receptor-Independent Pathway. <i>Immunity</i> , 2006, 24, 787-799.	6.6	91
42	IL-2 gets with the program. <i>Nature Immunology</i> , 2006, 7, 798-800.	7.0	4
43	The generation of protective memory-like CD8+ T cells during homeostatic proliferation requires CD4+ T cells. <i>Nature Immunology</i> , 2006, 7, 475-481.	7.0	193
44	Duration of CTL activation regulates IL-2 production required for autonomous clonal expansion. <i>European Journal of Immunology</i> , 2006, 36, 1707-1717.	1.6	18
45	Cytosolic Entry Controls CD8 + -T-Cell Potency during Bacterial Infection. <i>Infection and Immunity</i> , 2006, 74, 6387-6397.	1.0	56
46	Lipid Raft Targeting of Hematopoietic Protein Tyrosine Phosphatase by Protein Kinase C $\zeta$ -Mediated Phosphorylation. <i>Molecular and Cellular Biology</i> , 2006, 26, 1806-1816.	1.1	32
47	CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. <i>Nature</i> , 2005, 434, 88-93.	13.7	547
48	Rescue of memory CD8+ T cell reactivity in peptide/TLR9 ligand immunization by codelivery of cytokines or CD40 ligation. <i>Virology</i> , 2005, 331, 151-158.	1.1	22
49	Removal of C-Terminal Src Kinase from the Immune Synapse by a New Binding Protein. <i>Molecular and Cellular Biology</i> , 2005, 25, 2227-2241.	1.1	31
50	Dlgh1 coordinates actin polymerization, synaptic T cell receptor and lipid raft aggregation, and effector function in T cells. <i>Journal of Experimental Medicine</i> , 2005, 201, 419-430.	4.2	107
51	Protein Kinase C $\zeta$ Is an Early Survival Factor Required for Differentiation of Effector CD8+ T Cells. <i>Journal of Immunology</i> , 2005, 175, 5126-5134.	0.4	59
52	Protective and Pathological Roles of Virus-Specific and Bystander CD8+T Cells in Herpetic Stromal Keratitis. <i>Journal of Immunology</i> , 2004, 173, 7575-7583.	0.4	41
53	IL-7 regulates basal homeostatic proliferation of antiviral CD4+T cell memory. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 9357-9362.	3.3	176
54	Lck Dephosphorylation at Tyr-394 and Inhibition of T Cell Antigen Receptor Signaling by Yersinia Phosphatase YopH. <i>Journal of Biological Chemistry</i> , 2004, 279, 4922-4928.	1.6	94

#	ARTICLE	IF	CITATIONS
55	CD154 is a negative regulator of autoaggressive CD8+ T cells in type 1 diabetes. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 9345-9350.	3.3	14
56	CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature, 2003, 421, 852-856.	13.7	1,443
57	Tyrosine phosphorylation of VHR phosphatase by ZAP-70. Nature Immunology, 2003, 4, 44-48.	7.0	94
58	Dynamic programming of CD8+ T lymphocyte responses. Nature Immunology, 2003, 4, 361-365.	7.0	357
59	Immunotherapy of established tumors using bone marrow transplantation with antigen gene-modified hematopoietic stem cells. Nature Medicine, 2003, 9, 952-958.	15.2	55
60	A Subset of Toll-Like Receptor Ligands Induces Cross-presentation by Bone Marrow-Derived Dendritic Cells. Journal of Immunology, 2003, 170, 4102-4110.	0.4	273
61	In Vivo Ligation of CD40 Enhances Priming Against the Endogenous Tumor Antigen and Promotes CD8+ T Cell Effector Function in SV40 T Antigen Transgenic Mice. Journal of Immunology, 2003, 171, 697-707.	0.4	74
62	Cutting Edge: A Crucial Role for B7-CD28 in Transmitting T Help from APC to CTL. Journal of Immunology, 2002, 169, 4094-4097.	0.4	54
63	Tumor Growth Enhances Cross-Presentation Leading to Limited T Cell Activation without Tolerance. Journal of Experimental Medicine, 2002, 195, 423-435.	4.2	120
64	CD40L Blockade Prevents Autoimmune Diabetes by Induction of Bitypic NK/DC Regulatory Cells. Immunity, 2002, 16, 403-415.	6.6	150
65	Herpetic stromal keratitis in the absence of viral antigen recognition. Cellular Immunology, 2002, 219, 108-118.	1.4	39
66	CD40 Signaling and Autoimmunity. , 2001, 5, 51-61.		12
67	Naïve CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nature Immunology, 2001, 2, 423-429.	7.0	769
68	The Roles of MHC Class II, CD40, and B7 Costimulation in CTL Induction by Plasmid DNA. Journal of Immunology, 2001, 166, 3061-3066.	0.4	47
69	Cross-Presentation of Glycoprotein 96-associated Antigens on Major Histocompatibility Complex Class I Molecules Requires Receptor-Mediated Endocytosis. Journal of Experimental Medicine, 2000, 191, 1965-1974.	4.2	325
70	Role of Antigen-Presenting Cells in Mediating Tolerance and Autoimmunity. Journal of Experimental Medicine, 2000, 191, 2021-2028.	4.2	148
71	Melanoma immunotherapy by targeted IL-2 depends on CD4+ T-cell help mediated by CD40/CD40L interaction. Journal of Clinical Investigation, 2000, 105, 1623-1630.	3.9	33
72	CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nature Medicine, 1999, 5, 774-779.	15.2	439

#	ARTICLE	IF	CITATIONS
73	T-cell help for cytotoxic T lymphocytes is mediated by CD40â€“CD40L interactions. <i>Nature</i> , 1998, 393, 480-483.	13.7	2,371
74	CD40â€“CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. <i>Seminars in Immunology</i> , 1998, 10, 443-448.	2.7	93
75	Activation or frustration of anti-tumor responses by T-cell-based immune modulation. <i>Seminars in Immunology</i> , 1997, 9, 323-327.	2.7	10
76	Harnessing self-reactivity in cancer immunotherapy. <i>Seminars in Immunology</i> , 1996, 8, 303-309.	2.7	23